A novel vascular homing peptide strategy to selectively enhance pulmonary drug efficacy in pulmonary arterial hypertension

American Journal of Pathology

Volumn 184, Issue 2, 2014, Pages 369-375

  Toba, Michie ^a   Alzoubi, Abdallah ^a   O'Neill, Kealan ^a   Abe, Kohtaro ^a   Urakami, Takeo ^b   Komatsu, Masanobu ^b   Alvarez, Diego ^a   Järvinen, Tero A H ^c   Mann, David ^d   Ruoslahti, Erkki ^b   McMurtry, Ivan F ^a   Oka, Masahiko ^a  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^b BURNHAM INSTITUTE   (United States)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d VBS Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CARSKNKDC; CELL PENETRATING PEPTIDE; FASUDIL; IMATINIB; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY LESION; ARTICLE; BLOOD VESSEL PERMEABILITY; COMPARATIVE STUDY; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG EFFECT; DRUG EFFICACY; HEMODYNAMIC PARAMETERS; HEMODYNAMICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPOXIA; ISOLATED LUNG; LUNG CIRCULATION; LUNG PARENCHYMA; MALE; MASS SPECTROMETRY; NONHUMAN; OCCLUSIVE PULMONARY ARTERIAL LESION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; PULMONARY VASCULAR PERMEABILITY; PULMONARY VASODILATION; RAT; TARGET CELL; THERAPY EFFECT; TREATMENT RESPONSE; VASODILATATION;

ADMINISTRATION, SUBLINGUAL; AMINO ACID SEQUENCE; ANIMALS; ARTERIAL OCCLUSIVE DISEASES; BENZAMIDES; DRUG DELIVERY SYSTEMS; HEMODYNAMICS; HYPERTENSION, PULMONARY; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MOLECULAR SEQUENCE DATA; PEPTIDES; PIPERAZINES; PULMONARY ARTERY; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84892367888     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2013.10.008     Document Type: Article

References (30)

1. N. Galie, A. Manes, L. Negro, M. Palazzini, M.L. Bacchi-Reggiani, and A. Branzi A meta-analysis of randomized controlled trials in pulmonary arterial hypertension Eur Heart J 30 2009 394 403
2. V.V. McLaughlin, S.L. Archer, D.B. Badesch, R.J. Barst, H.W. Farber, J.R. Lindner, M.A. Mathier, M.D. McGoon, M.H. Park, R.S. Rosenson, L.J. Rubin, V.F. Tapson, J. Varga, R.A. Harrington, J.L. Anderson, E.R. Bates, C.R. Bridges, M.J. Eisenberg, V.A. Ferrari, C.L. Grines, M.A. Hlatky, A.K. Jacobs, S. Kaul, R.C. Lichtenberg, J.R. Lindner, D.J. Moliterno, D. Mukherjee, G.M. Pohost, R.S. Rosenson, R.S. Schofield, S.J. Shubrooks, J.H. Stein, C.M. Tracy, H.H. Weitz, and D.J. Wesley ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology foundation task force on expert consensus documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association Circulation 119 2009 2250 2294
3. K. Abe, H. Shimokawa, K. Morikawa, T. Uwatoku, K. Oi, Y. Matsumoto, T. Hattori, Y. Nakashima, K. Kaibuchi, K. Sueishi, and A. Takeshit Long-term treatment with a rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats Circ Res 94 2004 385 393
4. T. Nagaoka, Y. Morio, N. Casanova, N. Bauer, S. Gebb, I. McMurtry, and M. Oka Rho/rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats Am J Physiol Lung Cell Mol Physiol 287 2004 L665 L672
5. M. Oka, N. Homma, L. Taraseviciene-Stewart, K.G. Morris, D. Kraskauskas, N. Burns, N.F. Voelkel, and I.F. McMurtry Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats Circ Res 100 2007 923 929
6. V.N. Parikh, R.C. Jin, S. Rabello, N. Gulbahce, K. White, A. Hale, K.A. Cottrill, R.S. Shaik, A.B. Waxman, Y.Y. Zhang, B.A. Maron, J.C. Hartner, Y. Fujiwara, S.H. Orkin, K.J. Haley, A.L. Barabasi, J. Loscalzo, and S.Y. Chan Microrna-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach Circulation 125 2012 1520 1532
7. K. Abe, M. Toba, A. Alzoubi, K. Koubsky, M. Ito, H. Ota, S. Gairhe, W.T. Gerthoffer, K.A. Fagan, I.F. McMurtry, and M. Oka Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats Am J Respir Cell Mol Biol 45 2011 804 808
8. R.T. Schermuly, E. Dony, H.A. Ghofrani, S. Pullamsetti, R. Savai, M. Roth, A. Sydykov, Y.J. Lai, N. Weissmann, W. Seeger, and F. Grimminger Reversal of experimental pulmonary hypertension by PDGF inhibition J Clin Invest 115 2005 2811 2821
9. E. Bussemaker, F. Pistrosch, S. Forster, K. Herbrig, P. Gross, J. Passauer, and R.P. Brandes Rho kinase contributes to basal vascular tone in humans: role of endothelium-derived nitric oxide Am J Physiol Heart Circ Physiol 293 2007 H541 H547
10. D.B. Casey, A.M. Badejo, J.S. Dhaliwal, J.L. Sikora, A. Fokin, N.H. Golwala, A.J. Greco, S.N. Murthy, B.D. Nossaman, A.L. Hyman, and P.J. Kadowitz Analysis of responses to the rho-kinase inhibitory-27632 in the pulmonary and systemic vascular bed of the rat Am J Physiol Heart Circ Physiol 299 2010 H184 H192
11. R. Kerkela, L. Grazette, R. Yacobi, C. Iliescu, R. Patten, C. Beahm, B. Walters, S. Shevtsov, S. Pesant, F.J. Clubb, A. Rosenzweig, R.N. Salomon, R.A. Van Etten, J. Alroy, J.B. Durand, and T. Force Cardiotoxicity of the cancer therapeutic agent imatinib mesylate Nat Med 12 2006 908 916
12. S.N. Murthy, B.D. Nossaman, and P.J. Kadowitz New approaches to the treatment of pulmonary hypertension: from bench to bedside Cardiol Rev 18 2010 76 84
13. T. Nagaoka, K.A. Fagan, S.A. Gebb, K.G. Morris, T. Suzuki, H. Shimokawa, I.F. McMurtry, and M. Oka Inhaled rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension Am J Respir Crit Care Med 171 2005 494 499
14. A.S. Melani Inhalatory therapy training: a priority challenge for the physician Acta Biomed 78 2007 233 245
15. H. Fujita, Y. Fukumoto, K. Saji, K. Sugimura, J. Demachi, J. Nawata, and H. Shimokawa Acute vasodilator effects of inhaled fasudil, a specific rho-kinase inhibitor, in patients with pulmonary arterial hypertension Heart Vessels 25 2010 144 149
16. E. Ruoslahti Vascular zip codes in angiogenesis and metastasis Biochem Soc Trans 32 2004 397 402
17. E. Ruoslahti Peptides as targeting elements and tissue penetration devices for nanoparticles Adv Mater 24 2012 3747 3756
18. K.N. Sugahara, T. Teesalu, P.P. Karmali, V.R. Kotamraju, L. Agemy, O.M. Girard, D. Hanahan, R.F. Mattrey, and E. Ruoslahti Tissue-penetrating delivery of compounds and nanoparticles into tumors Cancer Cell 16 2009 510 520
19. T. Teesalu, K.N. Sugahara, V.R. Kotamraju, and E. Ruoslahti C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration Proc Natl Acad Sci U S A 106 2009 16157 16162
20. K.N. Sugahara, T. Teesalu, P.P. Karmali, V.R. Kotamraju, L. Agemy, D.R. Greenwald, and E. Ruoslahti Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs Science 328 2010 1031 1035
21. T.A.H. Järvinen, and E. Ruoslahti Molecular changes in the vasculature of injured tissues Am J Pathol 171 2007 702 711
22. T.A.H. Järvinen, and E. Ruoslahti Target-seeking antifibrotic compound enhances wound healing and suppresses scar formation in mice Proc Natl Acad Sci U S A 107 2010 21671 21676
23. T.A.H. Järvinen, and E. Ruoslahti Targeted antiscarring therapy for tissue injuries Adv Wound Care 2 2013 50 54
24. T. Urakami, T.A. Jarvinen, M. Toba, J. Sawada, N. Ambalavanan, D. Mann, I. McMurtry, M. Oka, E. Ruoslahti, and M. Komatsu Peptide-directed highly selective targeting of pulmonary arterial hypertension Am J Pathol 178 2011 2489 2495
25. K. Abe, M. Toba, A. Alzoubi, M. Ito, K.A. Fagan, C.D. Cool, N.F. Voelkel, I.F. McMurtry, and M. Oka Formation of plexiform lesions in experimental severe pulmonary arterial hypertension Circulation 121 2010 2747 2754
26. D.F. Alvarez, J.A. King, D. Weber, E. Addison, W. Liedtke, and M.I. Townsley Transient receptor potential vanilloid 4-mediated disruption of the alveolar septal barrier: a novel mechanism of acute lung injury Circ Res 99 2006 988 995
27. L. Taraseviciene-Stewart, Y. Kasahara, L. Alger, P. Hirth, G. Mc Mahon, J. Waltenberger, N.F. Voelkel, and R.M. Tuder Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension FASEB J 15 2001 427 438
28. E.A. Pankey, S. Thammasibon, G.F. Lasker, S. Baber, J.A. Lasky, and P.J. Kadowitz Imatinib attenuates monocrotaline pulmonary hypertension and has potent vasodilator activity in the pulmonary and systemic vascular beds in the rat Am J Physiol Heart Circ Physiol 305 2013 H1288 H1296
29. S.J. Bogdanowich-Knipp, S. Chakrabarti, T.D. Williams, R.K. Dillman, and T.J. Siahaan Solution stability of linear vs. cyclic RGD peptides J Pept Res 53 1999 530 541
30. V.F. Patel, F. Liu, and M.B. Brown Advances in oral transmucosal drug delivery J Control Release 153 2011 106 116